Protein Quantitative Trait Loci Identify Novel Candidates Modulating Cellular Response to Chemotherapy

PLoS Genetics

Volumn 10, Issue 4, 2014, Pages

  Stark, Amy L ^a   Hause Jr , Ronald J ^a,b,c   Gorsic, Lidija K ^a   Antao, Nirav N ^a   Wong, Shan S ^a   Chung, Sophie H ^a   Gill, Daniel F ^a   Im, Hae K ^a   Myers, Jamie L ^a   White, Kevin P ^a,c   Jones, Richard Baker ^a,b,c   Dolan, M Eileen ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PACLITAXEL; PROTEOME; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR; TRANSCRIPTOME; ANTINEOPLASTIC AGENT; PROTEIN;

APOPTOSIS; ARTICLE; CELLULAR STRESS RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG RESPONSE; GENE; GENETIC ASSOCIATION; GENETIC VARIABILITY; HAPLOTYPE MAP; HUMAN; HUMAN CELL; LYMPHOBLASTOID CELL LINE; PILOT STUDY; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN MICROARRAY; PROTEIN TARGETING; QUANTITATIVE TRAIT LOCUS; SINGLE NUCLEOTIDE POLYMORPHISM; SMC1A GENE; STEADY STATE; YORUBA (PEOPLE); ZNF569 GENE; DRUG EFFECTS; GENETICS; GENOTYPE; HUMAN GENOME; PHARMACOGENETICS; PHENOTYPE; PROCEDURES; PROTEOMICS; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CISPLATIN; GENOME, HUMAN; GENOME-WIDE ASSOCIATION STUDY; GENOTYPE; HAPMAP PROJECT; HUMANS; PACLITAXEL; PHARMACOGENETICS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEINS; PROTEOME; PROTEOMICS; QUANTITATIVE TRAIT LOCI; TRANSCRIPTION FACTORS; TRANSCRIPTOME;

EID: 84901334162     PISSN: 15537390     EISSN: 15537404     Source Type: Journal    
DOI: 10.1371/journal.pgen.1004192     Document Type: Article

References (66)

1. Wheeler HE, Dolan ME, (2012) Lymphoblastoid cell lines in pharmacogenomic discovery and clinical translation. Pharmacogenomics 13: 55-70.
2. Wheeler HE, Gamazon ER, Wing C, Njiaju UO, Njoku C, et al. (2013) Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy. Clin Cancer Res 19: 491-499.
3. Mitra AK, Crews KR, Pounds S, Cao X, Feldberg T, et al. (2011) Genetic variants in cytosolic 5′-nucleotidase II are associated with its expression and cytarabine sensitivity in HapMap cell lines and in patients with acute myeloid leukemia. J Pharmacol Exp Ther 339: 9-23.
4. Ziliak D, O'Donnell PH, Im HK, Gamazon ER, Chen P, et al. (2011) Germline polymorphisms discovered via a cell-based, genome-wide approach predict platinum response in head and neck cancers. Transl Res 157: 265-272.
5. Huang RS, Johnatty SE, Gamazon ER, Im HK, Ziliak D, et al. (2011) Platinum sensitivity-related germline polymorphism discovered via a cell-based approach and analysis of its association with outcome in ovarian cancer patients. Clin Cancer Res 17: 5490-5500.
6. Niu N, Schaid DJ, Abo RP, Kalari K, Fridley BL, et al. (2012) Genetic association with overall survival of taxane-treated lung cancer patients- a genome-wide association study in human lymphoblastoid cell lines followed by a clinical association study. BMC Cancer 12: 422.
7. Brown CC, Havener TM, Medina MW, Auman JT, Mangravite LM, et al. (2012) A genome-wide association analysis of temozolomide response using lymphoblastoid cell lines shows a clinically relevant association with MGMT. Pharmacogenet Genomics 22: 796-802.
8. O'Donnell PH, Stark AL, Gamazon ER, Wheeler HE, McIlwee BE, et al. (2012) Identification of novel germline polymorphisms governing capecitabine sensitivity. Cancer 118: 4063-4073.
9. Wheeler HE, Gamazon ER, Stark AL, O'Donnell PH, Gorsic LK, et al. (2013) Genome-wide meta-analysis identifies variants associated with platinating agent susceptibility across populations. Pharmacogenomics J 13: 35-43.
10. Hartford CM, Duan S, Delaney SM, Mi S, Kistner EO, et al. (2009) Population-specific genetic variants important in susceptibility to cytarabine arabinoside cytotoxicity. Blood 113: 2145-2153.
11. Huang RS, Duan S, Bleibel WK, Kistner EO, Zhang W, et al. (2007) A genome-wide approach to identify genetic variants that contribute to etoposide-induced cytotoxicity. Proc Natl Acad Sci U S A 104: 9758-9763.
12. Duan S, Huang RS, Zhang W, Bleibel WK, Roe CA, et al. (2008) Genetic architecture of transcript-level variation in humans. Am J Hum Genet 82: 1101-1113.
13. Stranger BE, Montgomery SB, Dimas AS, Parts L, Stegle O, et al. (2012) Patterns of cis regulatory variation in diverse human populations. PLoS Genet 8: e1002639.
14. Stranger BE, Nica AC, Forrest MS, Dimas A, Bird CP, et al. (2007) Population genomics of human gene expression. Nat Genet 39: 1217-1224.
15. Veyrieras JB, Kudaravalli S, Kim SY, Dermitzakis ET, Gilad Y, et al. (2008) High-resolution mapping of expression-QTLs yields insight into human gene regulation. PLoS Genet 4: e1000214.
16. Pickrell JK, Marioni JC, Pai AA, Degner JF, Engelhardt BE, et al. (2010) Understanding mechanisms underlying human gene expression variation with RNA sequencing. Nature 464: 768-772.
17. Bell JT, Pai AA, Pickrell JK, Gaffney DJ, Pique-Regi R, et al. (2011) DNA methylation patterns associate with genetic and gene expression variation in HapMap cell lines. Genome Biol 12: R10.
18. Pai AA, Cain CE, Mizrahi-Man O, De Leon S, Lewellen N, et al. (2012) The contribution of RNA decay quantitative trait loci to inter-individual variation in steady-state gene expression levels. PLoS Genet 8: e1003000.
19. Degner JF, Pai AA, Pique-Regi R, Veyrieras JB, Gaffney DJ, et al. (2012) DNase I sensitivity QTLs are a major determinant of human expression variation. Nature 482: 390-394.
20. Gamazon ER, Ziliak D, Im HK, LaCroix B, Park DS, et al. (2012) Genetic architecture of microRNA expression: implications for the transcriptome and complex traits. Am J Hum Genet 90: 1046-1063.
21. Ko DC, Gamazon ER, Shukla KP, Pfuetzner RA, Whittington D, et al. (2012) Functional genetic screen of human diversity reveals that a methionine salvage enzyme regulates inflammatory cell death. Proc Natl Acad Sci U S A 109: E2343-2352.
22. Kato T, Hayashi-Takagi A, Toyota T, Yoshikawa T, Iwamoto K, (2011) Gene expression analysis in lymphoblastoid cells as a potential biomarker of bipolar disorder. J Hum Genet 56: 779-783.
23. Oved K, Morag A, Pasmanik-Chor M, Oron-Karni V, Shomron N, et al. (2012) Genome-wide miRNA expression profiling of human lymphoblastoid cell lines identifies tentative SSRI antidepressant response biomarkers. Pharmacogenomics 13: 1129-1139.
24. Morag A, Oved K, Gurwitz D, (2013) Sex differences in human lymphoblastoid cells sensitivities to antipsychotic drugs. J Mol Neurosci 49: 554-558.
25. Gamazon ER, Huang RS, Cox NJ, Dolan ME, (2010) Chemotherapeutic drug susceptibility associated SNPs are enriched in expression quantitative trait loci. Proc Natl Acad Sci U S A 107: 9287-9292.
26. Chen G, Gharib TG, Huang CC, Taylor JM, Misek DE, et al. (2002) Discordant protein and mRNA expression in lung adenocarcinomas. Mol Cell Proteomics 1: 304-313.
27. Gygi SP, Rochon Y, Franza BR, Aebersold R, (1999) Correlation between protein and mRNA abundance in yeast. Mol Cell Biol 19: 1720-1730.
28. Nishizuka S, Charboneau L, Young L, Major S, Reinhold WC, et al. (2003) Proteomic profiling of the NCI-60 cancer cell lines using new high-density reverse-phase lysate microarrays. Proc Natl Acad Sci U S A 100: 14229-14234.
29. Shankavaram UT, Reinhold WC, Nishizuka S, Major S, Morita D, et al. (2007) Transcript and protein expression profiles of the NCI-60 cancer cell panel: an integromic microarray study. Mol Cancer Ther 6: 820-832.
30. Vogel C, Abreu Rde S, Ko D, Le SY, Shapiro BA, et al. (2010) Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Mol Syst Biol 6: 400.
31. Mwanda WO, Orem J, Fu P, Banura C, Kakembo J, et al. (2009) Dose-modified oral chemotherapy in the treatment of AIDS-related non-Hodgkin's lymphoma in East Africa. J Clin Oncol 27: 3480-3488.
32. Ciaccio MF, Wagner JP, Chuu CP, Lauffenburger DA, Jones RB, (2010) Systems analysis of EGF receptor signaling dynamics with microwestern arrays. Nat Methods 7: 148-155.
33. Hause RJ, Kim HD, Leung KK, Jones RB, (2011) Targeted protein-omic methods are bridging the gap between proteomic and hypothesis-driven protein analysis approaches. Expert Rev Proteomics 8: 565-575.
34. Zwelling LA, Kohn KW, (1979) Mechanism of action of cis-dichlorodiammineplatinum(II). Cancer Treat Rep 63: 1439-1444.
35. Rowinsky EK, Cazenave LA, Donehower RC, (1990) Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 82: 1247-1259.
36. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN, (1993) The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19: 351-386.
37. Ricci MS, Zong WX, (2006) Chemotherapeutic approaches for targeting cell death pathways. Oncologist 11: 342-357.
38. Im HK, Gamazon ER, Stark AL, Huang RS, Cox NJ, et al. (2012) Mixed effects modeling of proliferation rates in cell-based models: consequence for pharmacogenomics and cancer. PLoS Genet 8: e1002525.
39. Zhang W, Duan S, Kistner EO, Bleibel WK, Huang RS, et al. (2008) Evaluation of genetic variation contributing to differences in gene expression between populations. Am J Hum Genet 82: 631-640.
40. Bergstrom Lind S, Artemenko KA, Elfineh L, Mayrhofer C, Zubarev RA, et al. (2011) Toward a comprehensive characterization of the phosphotyrosine proteome. Cell Signal 23: 1387-1395.
41. Rojas AM, Sanchez-Pulido L, Futterer A, van Wely KH, Martinez AC, et al. (2005) Death inducer obliterator protein 1 in the context of DNA regulation. Sequence analyses of distant homologues point to a novel functional role. FEBS J 272: 3505-3511.
42. Le XF, Bast RC Jr, (2011) Src family kinases and paclitaxel sensitivity. Cancer Biol Ther 12: 260-269.
43. Chen T, Pengetnze Y, Taylor CC, (2005) Src inhibition enhances paclitaxel cytotoxicity in ovarian cancer cells by caspase-9-independent activation of caspase-3. Mol Cancer Ther 4: 217-224.
44. Van Waardenburg RC, Prins J, Meijer C, Uges DR, De Vries EG, et al. (1996) Effects of c-myc oncogene modulation on drug resistance in human small cell lung carcinoma cell lines. Anticancer Res 16: 1963-1970.
45. Walker TL, White JD, Esdale WJ, Burton MA, DeCruz EE, (1996) Tumour cells surviving in vivo cisplatin chemotherapy display elevated c-myc expression. Br J Cancer 73: 610-614.
46. Gu F, Ma Y, Zhang Z, Zhao J, Kobayashi H, et al. (2010) Expression of Stat3 and Notch1 is associated with cisplatin resistance in head and neck squamous cell carcinoma. Oncol Rep 23: 671-676.
47. Ikuta K, Takemura K, Kihara M, Nishimura M, Ueda N, et al. (2005) Overexpression of constitutive signal transducer and activator of transcription 3 mRNA in cisplatin-resistant human non-small cell lung cancer cells. Oncol Rep 13: 217-222.
48. Kato K, Nomoto M, Izumi H, Ise T, Nakano S, et al. (2000) Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells. Biochim Biophys Acta 1493: 91-100.
49. Su WP, Cheng FY, Shieh DB, Yeh CS, Su WC, (2012) PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine 7: 4269-4283.
50. Walker SR, Chaudhury M, Frank DA, (2011) STAT3 Inhibition by Microtubule-Targeted Drugs: Dual Molecular Effects of Chemotherapeutic Agents. Mol Cell Pharmacol 3: 13-19.
51. Wu H, Cao Y, Weng D, Xing H, Song X, et al. (2008) Effect of tumor suppressor gene PTEN on the resistance to cisplatin in human ovarian cancer cell lines and related mechanisms. Cancer Lett 271: 260-271.
52. Kim ST, Xu B, Kastan MB, (2002) Involvement of the cohesin protein, Smc1, in Atm-dependent and independent responses to DNA damage. Genes Dev 16: 560-570.
53. Mannini L, Liu J, Krantz ID, Musio A, (2010) Spectrum and consequences of SMC1A mutations: the unexpected involvement of a core component of cohesin in human disease. Hum Mutat 31: 5-10.
54. Barber TD, McManus K, Yuen KW, Reis M, Parmigiani G, et al. (2008) Chromatid cohesion defects may underlie chromosome instability in human colorectal cancers. Proc Natl Acad Sci U S A 105: 3443-3448.
55. Mannini L, Menga S, Tonelli A, Zanotti S, Bassi MT, et al. (2012) SMC1A codon 496 mutations affect the cellular response to genotoxic treatments. Am J Med Genet A 158A: 224-228.
56. Chen S, Blank JL, Peters T, Liu XJ, Rappoli DM, et al. (2010) Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res 70: 4318-4326.
57. Yamaguchi H, Durell SR, Chatterjee DK, Anderson CW, Appella E, (2007) The Wip1 phosphatase PPM1D dephosphorylates SQ/TQ motifs in checkpoint substrates phosphorylated by PI3K-like kinases. Biochemistry 46: 12594-12603.
58. Huang X, Yuan W, Huang W, Bai Y, Deng Y, et al. (2006) ZNF569, a novel KRAB-containing zinc finger protein, suppresses MAPK signaling pathway. Biochem Biophys Res Commun 346: 621-628.
59. Zhu C, Qi X, Chen Y, Sun B, Dai Y, et al. (2011) PI3K/Akt and MAPK/ERK1/2 signaling pathways are involved in IGF-1-induced VEGF-C upregulation in breast cancer. J Cancer Res Clin Oncol 137: 1587-1594.
60. Slichenmyer WJ, Von Hoff DD, (1991) Taxol: a new and effective anti-cancer drug. Anticancer Drugs 2: 519-530.
61. Wen Y, Gamazon ER, Bleibel WK, Wing C, Mi S, et al. (2012) An eQTL-based method identifies CTTN and ZMAT3 as pemetrexed susceptibility markers. Hum Mol Genet 21: 1470-1480.
62. Nicolae DL, Gamazon E, Zhang W, Duan S, Dolan ME, et al. (2010) Trait-associated SNPs are more likely to be eQTLs: annotation to enhance discovery from GWAS. PLoS Genet 6: e1000888.
63. Gaffney DJ, Veyrieras JB, Degner JF, Pique-Regi R, Pai AA, et al. (2012) Dissecting the regulatory architecture of gene expression QTLs. Genome Biol 13: R7.
64. Fu J, Wolfs MG, Deelen P, Westra HJ, Fehrmann RS, et al. (2012) Unraveling the regulatory mechanisms underlying tissue-dependent genetic variation of gene expression. PLoS Genet 8: e1002431.
65. Huang RS, Duan S, Shukla SJ, Kistner EO, Clark TA, et al. (2007) Identification of genetic variants contributing to cisplatin-induced cytotoxicity by use of a genomewide approach. Am J Hum Genet 81: 427-437.
66. Njiaju UO, Gamazon ER, Gorsic LK, Delaney SM, Wheeler HE, et al. (2012) Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel. Pharmacogenet Genomics 22: 498-507.